Narrow search
Showing 1 - 10 of 1,974
Cover Image
Creating R&D Incentives for Medicines for Neglected Diseases : An Economic Analysis of Parallel Imports, Patents, and Alternative Mechanisms to Stimulate Pharmaceutical Research
Müller-Langer, Frank - 2009
This book is the revised version of a doctoral thesis written at the Graduiertenkolleg Law and Economics at Hamburg University. It addresses the market failure with respect to R&D for medicines for tropical diseases and the lack of access to affordable medicines in poor countries. Tropical...
Persistent link: https://www.econbiz.de/10013521260
Cover Image
Treatments and a vaccine for COVID-19: The need for coordinating policies on R&D, manufacturing and access
OECD - 2020
This brief discusses policies needed to ensure equitable and universal access by all those in need globally to future vaccines for SARS-Cov-2, the virus that causes COVID-19, and treatments for the disease. It provides a snapshot of the vaccine and drug candidates in the current R&D pipeline. It...
Persistent link: https://www.econbiz.de/10012630217
Cover Image
Patents for Covid-19 vaccines are based on public research: a case study on the privatization of knowledge
Florio, Massimo - 2021 - This version October 11, 2021
Persistent link: https://www.econbiz.de/10012642904
Cover Image
Patenting government funded innovations as a strategy to increase budget for academic vaccine R&D
Songane, Mario - 2019
Persistent link: https://www.econbiz.de/10012138368
Cover Image
COVID-19 vaccine development in a Quadruple Helix innovation system : uncovering the preferences of the fourth helix in the UAE
Niankara, Ibrahim; Muqattash, Riham Suleiman; Niankara, … - In: Journal of open innovation : technology, market, and … 6 (2020) 4/132, pp. 1-25
insights for evidence based policy making that should increase the effectiveness of any prospective COVID-19 vaccination …
Persistent link: https://www.econbiz.de/10012315335
Cover Image
Innovative Influenza Vaccination Policy : Targeting Last Season's Patients
Yamin, Dan; Gavious, Arieh; Solnik, Eyal; Davidovitch, Nadav - 2014
Background: Influenza vaccination is the most efficient and cost-effective method to prevent influenza. WHO …/CDC recommendations have never considered the effect of previous individual illness on determining future vaccination policy for that …’s patients have between a 3.1to 5 higher probability to become infected, showing that a vaccination policy that prioritizes last …
Persistent link: https://www.econbiz.de/10014164239
Cover Image
Cost-Effectiveness of 23-Valent Pneumococcal Vaccine in Catalonia (Spain)
Plans-Rubio, Pedro - 2007
OBJECTIVE: In this study, cost-effectiveness of the 23-valent pneumococcal vaccination was assessed in Catalonia (Spain … achieved with the intervention. Vaccination costs were calculated taking into account a cost of 11.51 per vaccine. Costs and … was obtained for the strategy consisting in the universal vaccination of individuals aged >5 years. The cost …
Persistent link: https://www.econbiz.de/10014055624
Cover Image
"Selling the monster" or the relevance of cultural-cognitive conditions in creating demand for innovation : the case of COVID-19 vaccines and beyond
Reale, Filippo Gian-Antonio - In: International journal of research, innovation and … 4 (2022) 1, pp. 16-30
Persistent link: https://www.econbiz.de/10014227886
Cover Image
Can Operation Warp Speed Serve as a Model for Accelerating Innovations Beyond COVID Vaccines?
D'Souza, Arielle; Hoyt, Kendall; Snyder, Christopher M.; … - National Bureau of Economic Research - 2024
Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...
Persistent link: https://www.econbiz.de/10015056157